Tandem Diabetes Care Announces Publication of Real-world Basal-IQ Predictive Low Glucose Suspend Technology Data in Diabetes Technology and Therapeutics Journal
“This data supports the overwhelmingly positive feedback we hear from our customers using Basal-IQ technology and the clinical improvement people often report experiencing after initiating its use,” said
Summary of Hypoglycemia Data Published in Diabetes Technology and Therapeutics1
A retrospective analysis was conducted using deidentified data from the t:connect® diabetes management application. The analysis included data from patients ages 6 and up who had used Basal-IQ technology for at least 21 days between
Use of the t:slim X2 insulin pump with Basal-IQ technology led to an immediate and sustained reduction in hypoglycemic events. In the sub-analysis of people who used a CGM-enabled t:slim X2 pump prior to initiation of Basal-IQ technology, introduction of the feature reduced the mean time spent below 70 mg/dL from 3.0 percent to 1.76 percent, which represents a 45 percent relative risk reduction of hypoglycemia. The sub-analysis of those with nine weeks of Basal-IQ technology use showed that mean time spent below 70 mg/dL decreased sharply on the first day of use and remained low (1.74 percent) over time. Other outcome measures included time in range, mean glucose, hyperglycemia, and total daily dose.
Muller L, Habif S, Leas S, Aronoff-Spencer E. Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort. Diab Technol Ther. 2019;21(9):474-484. DOI: 10.1089/dia.2019.0190
Link to full article (open access): https://www.liebertpub.com/doi/10.1089/dia.2019.0190
About the t:slim X2 Insulin Pump with Basal-IQ Technology
The simple-to-use t:slim X2 insulin pump with Basal-IQ predictive low glucose suspend technology uses glucose values from an integrated Dexcom G6 continuous glucose monitor to predict and help prevent lows with zero fingersticks*. The t:slim X2 pump includes advanced features like a large color touchscreen, rechargeable battery, Bluetooth® wireless technology, USB connectivity and watertight construction (IPX7)2. It is capable of remote software updates using a personal computer, offering the potential for in-warranty users to access new features as they meet necessary regulatory requirements3. The t:slim X2 pump is up to 38 percent smaller than other insulin pumps and holds up to 300 units of insulin.4
Free Basal-IQ Technology Demo App
Tandem’s free t:simulator™ app lets users experience the touchscreen interface of the t:slim X2 insulin pump with Basal-IQ technology directly on a mobile device. For more information and to download the app, visit http://www.tandemdiabetes.com/tsimulator.
Free t:slim X2 Pump Software Updates Through End of 2020
Tandem is the only company that offers remote software updates for its insulin pumps as new features are approved by the
For additional product and safety information, or to begin the order process, visit www.tandemdiabetes.com/tslimX2
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the ability of the t:slim X2 pump to provide remote feature updates, the timing and outcome of regulatory approvals for new product features and updates, and the ability of our products to improve customer satisfaction and clinical outcomes. These statements are subject to numerous risks and uncertainties, including the risks that technical problems may prevent or delay remote software updates, regulatory agencies may fail to approve new product features or updates on our expected timeframe or at all, and the level of customer satisfaction from the use of our products and features may be different from what we expect, as well as other risks identified in Tandem’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, respectively, and other documents we file with the
* If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Dexcom G6 CGM sold separately.
1 DTT reference
2 Tested to a depth of 3 feet for 30 minutes
3 Additional feature updates are not currently available for the t:slim X2 pump with Basal-IQ technology and are subject to future
4 38 percent smaller than MiniMed 630G and 670G and at least 28 percent smaller than MiniMed 530G, Animas Vibe and Omnipod System. Data on file,
5 Additional feature updates are not currently available for the t:slim X2 pump with Basal-IQ technology and are subject to future
Steve Sabicer, (714) 907-6264, email@example.com
Susan Morrison, (858) 366-6900 x7005, firstname.lastname@example.org